Towards selective inhibitors of adenylyl cyclase toxin from Bordetella pertussis

Trends in Microbiology

Volumn 20, Issue 7, 2012, Pages 343-351

  Seifert, Roland ^a   Dove, Stefan ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adenylyl cyclase; Bordetella pertussis; Calmodulin; CyaA; Cyclic AMP; Inhibitor

Indexed keywords

4 [4 (4 NITROPHENYL)THIAZOYLYLAMINO]BENZENE SULFONAMIDE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]ADENINE DIPHOSPHATE; ADENYLATE CYCLASE INHIBITOR; ADENYLATE CYCLASE TOXIN; ANTIINFECTIVE AGENT; CALMIDOZALIUM; CALMODULIN; ETHYL 5 AMINOPYRAZOLO[1,5 ALPHA]QUINAZOLINE 3 CARBOXYLATE; LYASE INHIBITOR; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BINDING AFFINITY; BORDETELLA PERTUSSIS; CONCENTRATION RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; REVIEW; TOXIN ANALYSIS;

ADENYLATE CYCLASE TOXIN; ANTI-BACTERIAL AGENTS; BORDETELLA PERTUSSIS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RIBONUCLEOTIDES;

BORDETELLA PERTUSSIS; MAMMALIA;

EID: 84862760801     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2012.04.002     Document Type: Review

References (53)

1. Crowcroft D., Pebody R.G. Recent developments in pertussis. Lancet 2006, 367:1926-1936.
2. Marzouqi I., et al. Development of improved vaccines against whooping cough: current status. Hum. Vaccin. 2010, 6:543-553.
3. Grenfell B. Boosting understanding of pertussis outbreaks. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:7279-7280.
4. Berger F., et al. Investigation on a pertussis outbreak in a military school: risk factors and approach to vaccine efficacy. Vaccine 2010, 28:5147-5152.
5. Miyashita N., et al. Outbreak of pertussis in a university laboratory. Intern. Med. 2011, 50:879-885.
6. Lehmann C., Benson P.A. Vaccine adherence in adolescents. Clin. Pediatr. 2009, 48:801-811.
7. Guiso N. Bordetella pertussis and pertussis vaccines. Clin. Infect. Dis. 2009, 49:1565-1569.
8. Ladant D., Ullmann A. Bordetella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol. 1999, 7:172-176.
9. Vojtova L., et al. Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr. Opin. Microbiol. 2006, 9:69-75.
10. Shrivastava R., Miller J.F. Virulence factor secretion and translocation by Bordetella species. Curr. Opin. Microbiol. 2009, 12:88-93.
11. Carbonetti N.H. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 2010, 5:455-469.
12. Tang W.J., Guo Q. The adenylyl cyclase activity of anthrax edema factor. Mol. Aspects Med. 2009, 30:423-430.
13. Guo Q., et al. Structural basis for the interaction of Bordetella pertussis adenylyl cyclase toxin with calmodulin. EMBO J. 2005, 24:3190-3201.
14. Sunahara R.K., Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signalling. Mol. Intervent. 2002, 2:168-184.
15. Sadana R., Dessauer C.W. Physiological roles for G protein-regulated adenylyl cyclase isoforms: insights from knockout and overexpression studies. Neurosignals 2009, 17:5-22.
16. Pierre S., et al. Capturing adenylyl cyclases as potential drug targets. Nat. Rev. Drug Discov. 2009, 8:321-335.
17. Seifert R., et al. Inhibitors of membranous adenylyl cyclases. Trends Pharmacol. Sci. 2012, 33:64-78.
18. Dessauer C.W., et al. The interactions of adenylate cyclases with P-site inhibitors. Trends Pharmacol. Sci. 1999, 20:205-210.
19. Johnson R.A., Shoshani I. Inhibition of Bordetella pertussis and Bacillus anthracis adenylyl cyclases by polyadenylate and 'P'-site agonists. J. Biol. Chem. 1990, 265:19035-19039.
20. Bushfield M., et al. Tissue levels, source, and regulation of 3'-AMP: an intracellular inhibitor of adenylyl cyclases. Mol. Pharmacol. 1990, 38:848-853.
21. Soelaiman S., et al. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 2003, 278:25990-25997.
22. Pinto C., et al. Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases. Biochem. Pharmacol. 2011, 82:358-370.
23. Erdorf M., et al. Impact of divalent cations on regulation of adenylyl cyclase isoforms by forskolin analogs. Biochem. Pharmacol. 2011, 82:1673-1681.
24. Shen Y., et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:3242-3247.
25. Shoshani I., et al. Inhibition of adenylyl cyclase by acyclic nucleoside phosphonate antiviral drugs. J. Biol. Chem. 1999, 274:34742-34744.
26. Viganò M., et al. Drug safety evaluation of adefovir in HBV infection. Expert Opin. Drug Saf. 2011, 10:809-818.
27. Weiss B., et al. Interaction of drugs with calmodulin. Biochemical, pharmacological and clinical implications. Biochem. Pharmacol. 1982, 31:2217-2226.
28. Johnson J.D., Wittenauer L.A. A fluorescent calmodulin that reports the binding of hydrophobic inhibitory ligands. Biochem. J. 1983, 211:473-479.
29. Gentile F., et al. Bordetella pertussis adenylate cyclase. Penetration into host cells. Eur. J. Biochem. 1988, 175:447-453.
30. 2+ pumps. Biochem. Pharmacol. 2000, 60:1797-1806.
31. Haunsø A., et al. Small ligands modulating the activity of mammalian adenylyl cyclases: a novel mode of inhibition by calmidazolium. Mol. Pharmacol. 2003, 63:624-631.
32. James L.R., et al. Inhibition of nitric oxide-activated guanylyl cyclase by calmodulin antagonists. Br. J. Pharmacol. 2009, 158:1454-1464.
33. Lee Y.S., et al. Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. Chem. Biol. 2004, 11:1139-1146.
34. Guo Q., et al. Protein-protein docking and analysis reveal that two homologous bacterial adenylyl cyclase toxins interact with calmodulin differently. J. Biol. Chem. 2008, 283:23836-23845.
35. Gille A., et al. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 2004, 279:19955-19969.
36. Mou T.C., et al. Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2'(3')-O-(N-methylanthraniloyl)-guanosine 5'-triphosphate. J. Biol. Chem. 2005, 280:7253-7261.
37. Mou T.C., et al. Broad specificity of mammalian adenylyl cyclase for interaction with 2',3'-substituted purine and pyrimidine nucleotide inhibitors. Mol. Pharmacol. 2006, 70:878-886.
38. Göttle M., et al. Molecular analysis of the interaction of Bordetella pertussis adenylyl cyclase with fluorescent nucleotides. Mol. Pharmacol. 2007, 72:526-535.
39. Suryanarayana S., et al. Differential inhibition of various adenylyl cyclase isoforms and soluble guanylyl cyclase by 2',3'-O-(2,4,6-trinitrophenyl)-substituted nucleoside 5'-triphosphates. J. Pharmacol. Exp. Ther. 2009, 330:687-695.
40. Hübner M., et al. Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-O-(N-methylanthraniloyl)-inosine 5'-triphosphate. Mol. Pharmacol. 2011, 80:87-96.
41. Geduhn J., et al. Bis-halogen-anthraniloyl-substituted nucleoside 5'-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin. J. Pharmacol. Exp. Ther. 2011, 336:104-115.
42. Gille A., Seifert R. 2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors. J. Biol. Chem. 2003, 278:12672-12679.
43. Göttle M., et al. Cytidylyl and uridylyl cyclase activity of Bacillus anthracis edema factor and Bordetella pertussis CyaA. Biochemistry 2010, 49:5494-5503.
44. Vougier S., et al. Essential role of methionine residues in calmodulin binding to Bordetella pertussis adenylate cyclase, as probed by selective oxidation and repair by the peptide methionine sulfoxide reductase. J. Biol. Chem. 2004, 279:30210-30218.
45. Rhoads A.R., Friedberg F. Sequence motifs for calmodulin recognition. FASEB J. 1997, 11:331-340.
46. Hoeflich K.P., Ikura M. Calmodulin in action: diversity in target recognition and activation mechanisms. Cell 2002, 108:739-742.
47. Schuler D., et al. Interactions of Bordetella pertussis adenylyl cyclase toxin CyaA with calmodulin mutants and calmodulin antagonists: comparison with membranous adenylyl cyclase I. Biochem. Pharmacol. 2012, 83:839-848.
48. Jameson D.M., Eccleston J.F. Fluorescent nucleotide analogs: synthesis and applications. Methods Enzymol. 1997, 278:363-390.
49. Hübner M., et al. Effect of MANT-nucleotides on L-type calcium currents in murine cardiomyocytes. Naunyn-Schmiedeberg's Arch. Pharmacol. 2011, 383:573-583.
50. Laux W.H., et al. Pro-nucleotide inhibitors of adenylyl cyclases in intact cells. J. Biol. Chem. 2004, 279:13317-13332.
51. Fabbro D., et al. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol. Biol. 2012, 795:1-34.
52. Spangler C.M., et al. A fluorimetric assay for real-time monitoring of adenylyl cyclase activity based on terbium norfloxacin. Anal. Biochem. 2008, 381:86-93.
53. Laine E., et al. Use of allostery to identify inhibitors of calmodulin-induced activation of Bacillus anthracis edema factor. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11277-11282.